Mitochondrial transplantation and platelet rich plasma for the treatment of non-alcoholic fatty liver disease
Open Access
- 27 October 2025
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (10) , 110054
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent global health concern, contributing to the development of insulin resistance, diabetes, cardiovascular disease, cirrhosis, and hepatocellular carcinoma. Since no approved drugs for the treatment of NAFLD exist, there is an urgent need for novel therapeutic strategies. Two such strategies are mitochondrial transplantation and platelet rich plasma (PRP) therapy. In preclinical NAFLD, mitochondrial transplantation alleviates steatosis by improving the hepatic imbalance between fatty acid utilization and synthesis. Moreover, it reduces excessive reactive oxygen species production and lipid peroxidation, thereby reducing inflammation and fibrosis. In contrast, PRP therapy ameliorates hepatic damage induced by xenobiotics by deactivating stellate cells, reducing fibrosis and apoptosis, and decreasing inflammation via NF-κB inhibition, while enhancing antioxidant defenses. These effects may be related to the improvement of NAFLD observed in a preclinical study. We propose that a combination of mitochondrial transplantation and PRP therapy may represent a novel approach for treating NAFLD by targeting different aspects of NAFLD in a complementary manner. We discuss the limitations of these therapies, as preclinical studies addressing NAFLD with these therapies are scarce, and there are no clinical trials in humans.Keywords
This publication has 86 references indexed in Scilit:
- Indications and contraindications to platelet‐rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections)Knee Surgery, Sports Traumatology, Arthroscopy, 2025
- Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030Internal and Emergency Medicine, 2025
- Mitochondrial alterations and signatures in hepatocellular carcinomaCancer and Metastasis Reviews, 2025
- The potential curative and hepatoprotective effects of platelet rich plasma on liver fibrosis in Schistosoma mansoni experimentally infected miceJournal of Parasitic Diseases, 2023
- Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)2021
- Interplay between NADH oxidation by complex I, glutathione redox state and sirtuin-3, and its role in the development of insulin resistanceBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Biologic response of human anterior cruciate ligamentocytes on collagen‐patches to platelet‐rich plasma formulations with and without leucocytesJournal of Orthopaedic Research, 2017
- Mitochondrial genome architecture in non‐alcoholic fatty liver diseaseThe Journal of Pathology, 2016
- The lysosomal-mitochondrial axis in free fatty acid–induced hepatic lipotoxicityHepatology, 2007
- Mitochondrial dysfunction in rat with nonalcoholic fatty liverBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2007